Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth

Investigators engineered a Natural Killer cell line to express CD64, the sole human high-affinity IgG Fcγ receptor, and bound these cells with antibodies to provide interchangeable tumor-targeting elements.